STRO Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of 16.99%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Sutro Biopharma, Inc. has a consensus price target of $21.25, signalling upside risk potential of 31.5%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $467.62 which suggests that it could grow by 48.74%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.546, which suggesting that the stock is 54.647% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 4.14x versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Crinetics Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -90972.73%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41%.

Sutro Biopharma, Inc. has a consensus price target of $21.25, signalling upside risk potential of 31.5%. On the other hand Crinetics Pharmaceuticals, Inc. has an analysts' consensus of $84.08 which suggests that it could grow by 96.9%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.546, which suggesting that the stock is 54.647% more volatile than S&P 500. In comparison Crinetics Pharmaceuticals, Inc. has a beta of 0.195, suggesting its less volatile than the S&P 500 by 80.492%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Crinetics Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than Crinetics Pharmaceuticals, Inc. quarterly revenues of $143K. Sutro Biopharma, Inc.'s net income of -$56.9M is higher than Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Crinetics Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 4.14x versus 2,591.22x for Crinetics Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of --. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Sutro Biopharma, Inc. has a consensus price target of $21.25, signalling upside risk potential of 31.5%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1625.63%. Given that GT Biopharma, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe GT Biopharma, Inc. is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.546, which suggesting that the stock is 54.647% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.887%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 4.14x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -103.13%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34%.

Sutro Biopharma, Inc. has a consensus price target of $21.25, signalling upside risk potential of 31.5%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $141.57 which suggests that it could grow by 44.36%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.546, which suggesting that the stock is 54.647% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.005, suggesting its more volatile than the S&P 500 by 100.46%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $51.3M. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 4.14x versus 35.81x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.